Dopamine therapy improves cognitive function in mild-to-moderate Alzheimer’s, study indicates

Written by Sharon Salt, Senior Editor

Rotigotine – a drug that acts on dopamine transmission in the brain – has been demonstrated to improve cognitive function in people with mild-to-moderate Alzheimer’s disease. The study, which has recently been published in JAMA Network Open, indicated that rotigotine did not show significant effect on memory functions, however, the drug improved frontal lobe executive function and patients’ ability to perform activities of daily living. “Rotigotine improved executive function, which helps patients with cognitive tasks, such as reasoning, judgement, working memory and orientation. It also improved their ability to complete routine daily activities like shopping, planning and even bathing, toileting...

To view this content, please register now for access

It's completely free